**Supplementary Table 3. Statistical analysis for comparing baseline and 6-month methylation risk score surrogates in the Dasatinib, Quercetin, and Fisetin study.**

|  |  |  |
| --- | --- | --- |
|  | **Mean** | **Baseline vs 6-month** |
|  | **Baseline** | **6-month** | **T-score** | **P-value** |
| **Epigenetic Age Zhang.** | -0.679 | -0.556 | -0.719 | 0.492 |
| **Alcohol** | -11.613 | -11.406 | -2.928 | 0.019 |
| **Body Fat** | -8.756 | -8.987 | 0.247 | 0.811 |
| **Body Mass Index** | -0.571 | -0.58 | 0.36 | 0.728 |
| **HDL Cholesterol** | 2.598 | 2.612 | -0.313 | 0.762 |
| **Smoking** | 2.699 | 2.581 | 1.45 | 0.185 |
| **Waist.Hip.Ratio** | -0.323 | -0.306 | -1.891 | 0.095 |
| **ADAMTS** | 0.1 | 0.104 | -1.311 | 0.226 |
| **Adiponectin** | -0.072 | -0.073 | 0.49 | 0.637 |
| **Afamin** | -0.01 | -0.01 | -0.279 | 0.787 |
| **Alpha L iduronidase** | 0.112 | 0.112 | -0.082 | 0.937 |
| **Aminoacylase 1** | -0.319 | -0.322 | 0.687 | 0.511 |
| **B2 microglobulin** | -0.376 | -0.376 | 0.066 | 0.949 |
| **BMP.1** | 0.115 | 0.121 | -2.644 | 0.03 |
| **CCL11** | -0.003 | -0.004 | 0.362 | 0.726 |
| **CCL17** | -0.428 | -0.431 | 1.266 | 0.241 |
| **CCL18** | -0.145 | -0.144 | -0.892 | 0.399 |
| **CCL21** | -0.131 | -0.133 | 0.968 | 0.362 |
| **CCL22** | -0.065 | -0.066 | 0.337 | 0.745 |
| **CCL25.C.C** | -0.061 | -0.062 | 1.089 | 0.308 |
| **CD163** | -0.246 | -0.244 | -0.666 | 0.524 |
| **CD209.antigen** | 0.134 | 0.139 | -1.453 | 0.184 |
| **CD48.antigen** | -0.157 | -0.158 | 0.267 | 0.797 |
| **CD6** | 0.097 | 0.096 | 0.342 | 0.741 |
| **CDL5** | -0.069 | -0.07 | 0.234 | 0.821 |
| **CHIT.1** | -0.173 | -0.173 | -0.071 | 0.945 |
| **CLEC11A.e1** | -0.005 | -0.015 | 1.792 | 0.111 |
| **CLEC11A.e2** | -0.145 | -0.153 | 1.798 | 0.11 |
| **Coagulation.factor.VII** | 0.049 | 0.048 | 0.353 | 0.733 |
| **Complement.C4** | 0.036 | 0.037 | -1.052 | 0.324 |
| **Complement.C5a** | 0.159 | 0.161 | -0.498 | 0.632 |
| **Complement.c9** | -0.009 | -0.013 | 0.756 | 0.471 |
| **Contactin.4** | 0.171 | 0.17 | 0.386 | 0.71 |
| **CRP** | -0.113 | -0.117 | 1.396 | 0.2 |
| **CRTAM** | 0.053 | 0.055 | -0.797 | 0.448 |
| **CXCL10** | 0.137 | 0.141 | -0.95 | 0.37 |
| **CXCL10.soma** | -0.347 | -0.346 | -0.206 | 0.842 |
| **CXCL11** | 0.097 | 0.101 | -0.703 | 0.502 |
| **CXCL11.soma** | -0.056 | -0.054 | -0.788 | 0.453 |
| **CXCL9** | -0.037 | -0.035 | -1.532 | 0.164 |
| **E.selectin** | -0.026 | -0.026 | -0.018 | 0.986 |
| **Ectodysplasin.A** | -0.216 | -0.219 | 1.531 | 0.164 |
| **EN.RAGE** | 0.051 | 0.047 | 1.278 | 0.237 |
| **ENPP7** | -0.017 | -0.015 | -0.203 | 0.844 |
| **ESM.1** | -0.244 | -0.247 | 1.814 | 0.107 |
| **EZR** | -0.019 | -0.018 | -0.495 | 0.634 |
| **FAP** | -0.143 | -0.141 | -1.418 | 0.194 |
| **FCER2** | -0.251 | -0.252 | 0.271 | 0.793 |
| **FCGR3A** | -0.203 | -0.207 | 1.06 | 0.32 |
| **FcRL2** | -0.175 | -0.176 | 0.479 | 0.645 |
| **FGF.21** | -0.116 | -0.113 | -1.642 | 0.139 |
| **G.CSF** | -0.015 | -0.016 | 0.418 | 0.687 |
| **Galectin.4** | -0.208 | -0.208 | -0.302 | 0.771 |
| **GDF.8** | 0.141 | 0.142 | -0.852 | 0.419 |
| **GHR** | 0.139 | 0.141 | -0.643 | 0.538 |
| **GPIba** | -0.362 | -0.363 | 0.141 | 0.892 |
| **Granulysin** | -0.115 | -0.112 | -0.76 | 0.469 |
| **Granzyme.A** | -0.034 | -0.035 | 0.326 | 0.753 |
| **GZMA** | -0.067 | -0.068 | 0.762 | 0.468 |
| **HCII** | 0.039 | 0.038 | 0.084 | 0.935 |
| **HGF** | 0.043 | 0.041 | 0.824 | 0.434 |
| **HGFA** | 0.358 | 0.359 | -0.499 | 0.631 |
| **HGFI** | 0.551 | 0.56 | -0.88 | 0.405 |
| **ICAM5** | -0.092 | -0.093 | 0.203 | 0.844 |
| **IGFBP.1** | -0.124 | -0.125 | 0.283 | 0.784 |
| **IGFBP.4** | -0.048 | -0.045 | -3.234 | 0.012 |
| **Insulin.receptor** | -0.136 | -0.137 | 0.54 | 0.604 |
| **Interleukin.19** | -0.011 | -0.009 | -0.67 | 0.522 |
| **L.selectin** | 0.051 | 0.051 | -0.206 | 0.842 |
| **LFT** | -0.005 | -0.007 | 0.747 | 0.476 |
| **LGALS3BP** | 0.008 | 0.006 | 1.019 | 0.338 |
| **LY9** | -0.124 | -0.123 | -0.265 | 0.798 |
| **Lymphotoxin.abeta** | -0.037 | -0.034 | -0.991 | 0.351 |
| **MIA** | 0.102 | 0.103 | -0.456 | 0.66 |
| **MMP.1.1** | -0.123 | -0.122 | -0.348 | 0.737 |
| **MMP.12** | -0.201 | -0.201 | 0.01 | 0.992 |
| **MMP.9** | -0.211 | -0.212 | 0.323 | 0.755 |
| **MMP.1** | -0.097 | -0.098 | 0.689 | 0.51 |
| **MRC2** | 0.043 | 0.043 | 0.011 | 0.992 |
| **Myeloperoxidase** | -0.001 | -0.001 | -0.047 | 0.964 |
| **N.CDase** | 0.105 | 0.106 | -0.572 | 0.583 |
| **NCAM.120** | 0.043 | 0.043 | 0.294 | 0.776 |
| **NEP** | -0.037 | -0.031 | -2.053 | 0.074 |
| **NMNAT1** | -0.05 | -0.05 | -0.392 | 0.705 |
| **NOTCH1** | 0.069 | 0.07 | -0.492 | 0.636 |
| **NRTK3** | 0.144 | 0.147 | -1.144 | 0.286 |
| **NTRK3** | 0.136 | 0.135 | 0.234 | 0.821 |
| **OSM** | 0.1 | 0.094 | 1.746 | 0.119 |
| **Osteomodulin** | 0.329 | 0.326 | 1.924 | 0.091 |
| **PAPP.A** | -0.402 | -0.399 | -0.426 | 0.681 |
| **PIGR** | -0.216 | -0.218 | 0.636 | 0.542 |
| **RARRES2** | 0.01 | 0.013 | -1.15 | 0.283 |
| **Resistin** | -0.122 | -0.126 | 0.93 | 0.379 |
| **S100.A9** | 0.035 | 0.034 | 0.345 | 0.739 |
| **Semaphorin.3E** | -0.057 | -0.057 | 0.245 | 0.813 |
| **SERPIN.A3** | 0.157 | 0.157 | 0.156 | 0.88 |
| **SHBG** | -0.068 | -0.07 | 0.834 | 0.428 |
| **SIGLEC1** | -0.043 | -0.042 | -0.524 | 0.614 |
| **SKR3** | 0.163 | 0.164 | -0.485 | 0.641 |
| **SLITRK5** | 0.148 | 0.154 | -1.471 | 0.18 |
| **SMPD1** | -0.034 | -0.034 | 0.06 | 0.953 |
| **Stanniocalcin.1** | -0.04 | -0.037 | -1.222 | 0.257 |
| **Testican.2** | -0.212 | -0.214 | 0.795 | 0.449 |
| **TGF.alpha** | 0.024 | 0.019 | 1.798 | 0.11 |
| **THBS2** | -0.116 | -0.119 | 0.996 | 0.348 |
| **TNFRSF17** | 0.013 | 0.012 | 1.069 | 0.316 |
| **TNFRSF1B** | -0.106 | -0.108 | 1.039 | 0.329 |
| **TPO** | -0.308 | -0.31 | 0.7 | 0.504 |
| **Trypsin.2** | -0.104 | -0.103 | -1.352 | 0.213 |
| **Tryptase.beta.2** | -0.174 | -0.174 | 0.043 | 0.967 |
| **VCAM1** | -0.008 | -0.008 | 0.012 | 0.991 |
| **VEGFA** | 0.125 | 0.124 | 0.255 | 0.805 |

We used methylation risk scores surrogates to predict and quantify predicted changes in circulating proteomic markers, as described in Marioni et al. The first two columns show the mean values for each immune cell proportion at each time point. The next columns have information about the t-test between baseline and 6-month test.